The neuroprotective and neurotrophic agent T-817MA for Alzheimer’s disease: Randomized, double-blind, placebo-controlled proof-of-concept trial outcomes
The neuroprotective and neurotrophic agent T-817MA for Alzheimer’s disease: Randomized, double-blind, placebo-controlled proof-of-concept trial outcomes
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started